Lisa K McNeil, Robert G K Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L Harris, Thomas R Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W Mayer, Michael W Pride, Kathrin U Jansen, Annaliesa S Anderson
Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories...
March 13, 2018: MBio